Latest & greatest articles for clopidogrel

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on clopidogrel or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on clopidogrel and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for clopidogrel

142. The effect of different treatment durations of clopidogrel in patients with non-ST-segment elevation acute coronary syndromes: a systematic review and value of information analysis

The effect of different treatment durations of clopidogrel in patients with non-ST-segment elevation acute coronary syndromes: a systematic review and value of information analysis The effect of different treatment durations of clopidogrel in patients with non-ST-segment elevation acute coronary syndromes: a systematic review and value of information analysis Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display, please try again

NIHR HTA programme2009

143. Intensifying Platelet Inhibition With Tirofiban in Poor Responders to Aspirin, Clopidogrel, or Both Agents Undergoing Elective Coronary Intervention

Intensifying Platelet Inhibition With Tirofiban in Poor Responders to Aspirin, Clopidogrel, or Both Agents Undergoing Elective Coronary Intervention 19528337 2009 06 30 2009 07 22 2014 11 20 1524-4539 119 25 2009 Jun 30 Circulation Circulation Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients (...) Showing Resistance to Aspirin and/or Resistance to Clopidogrel study. 3215-22 10.1161/CIRCULATIONAHA.108.833236 Inhibition of platelet aggregation after aspirin or clopidogrel intake varies greatly among patients, and previous studies have suggested that poor response to oral antiplatelet agents may increase the risk of thrombotic events, especially after coronary angioplasty. Whether this reflects suboptimal platelet inhibition per se, which might benefit from more potent antiplatelet agents

EvidenceUpdates2009

144. Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardi

Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardi 19451347 2009 06 02 2009 06 25 2015 11 19 1524-4539 119 21 2009 Jun 02 Circulation Circulation Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess (...) Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarction. 2758-64 10.1161/CIRCULATIONAHA.108.833665 Prasugrel is a novel thienopyridine that reduces new or recurrent myocardial infarctions (MIs) compared with clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention. This effect must be balanced

EvidenceUpdates2009

145. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel

A population-based study of the drug interaction between proton pump inhibitors and clopidogrel 19176635 2009 03 31 2009 05 04 2014 12 10 1488-2329 180 7 2009 Mar 31 CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne CMAJ A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. 713-8 10.1503/cmaj.082001 Most proton pump inhibitors inhibit the bioactivation of clopidogrel to its active metabolite. The clinical (...) significance of this drug interaction is unknown. We conducted a population-based nested case-control study among patients aged 66 years or older who commenced clopidogrel between Apr. 1, 2002, and Dec. 31, 2007, following hospital discharge after treatment of acute myocardial infarction. The cases in our study were those readmitted with acute myocardial infarction within 90 days after discharge. We performed a secondary analysis considering events within 1 year. Event-free controls (at a ratio of 3:1

EvidenceUpdates2009 Full Text: Link to full Text with Trip Pro

146. Randomized Trial of Warfarin, Aspirin, and Clopidogrel in Patients With Chronic Heart Failure: The Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) Trial

Randomized Trial of Warfarin, Aspirin, and Clopidogrel in Patients With Chronic Heart Failure: The Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) Trial 19289640 2009 03 31 2009 04 24 2013 11 21 1524-4539 119 12 2009 Mar 31 Circulation Circulation Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. 1616-24 10.1161/CIRCULATIONAHA.108.801753 Chronic heart (...) ) or clopidogrel (75 mg once daily) had a 30-month enrollment period and a minimum of 12 months of treatment. We enrolled 1587 men and women >/=18 years of age with symptomatic heart failure for at least 3 months who were in sinus rhythm and had left ventricular ejection fraction of

EvidenceUpdates2009

147. Bivalirudin and Clopidogrel With and Without Eptifibatide for Elective Stenting: Effects on Platelet Function, Thrombelastographic Indexes, and Their Relation to Periprocedural Infarction

Bivalirudin and Clopidogrel With and Without Eptifibatide for Elective Stenting: Effects on Platelet Function, Thrombelastographic Indexes, and Their Relation to Periprocedural Infarction 19232896 2009 02 23 2009 03 16 2016 11 25 1558-3597 53 8 2009 Feb 24 Journal of the American College of Cardiology J. Am. Coll. Cardiol. Bivalirudin and clopidogrel with and without eptifibatide for elective stenting: effects on platelet function, thrombelastographic indexes, and their relation (...) to periprocedural infarction results of the CLEAR PLATELETS-2 (Clopidogrel with Eptifibatide to Arrest the Reactivity of Platelets) study. 648-57 10.1016/j.jacc.2008.10.045 The primary objective of this study was to compare the effect of therapy with bivalirudin alone versus bivalirudin plus eptifibatide on platelet reactivity measured by turbidometric aggregometry and thrombin-induced platelet-fibrin clot strength (TIP-FCS) measured by thrombelastography in percutaneous coronary intervention (PCI) patients

EvidenceUpdates2009

148. The relative efficacy and safety of clopidogrel in women and men: a sex-specific collaborative meta-analysis

The relative efficacy and safety of clopidogrel in women and men: a sex-specific collaborative meta-analysis The relative efficacy and safety of clopidogrel in women and men: a sex-specific collaborative meta-analysis The relative efficacy and safety of clopidogrel in women and men: a sex-specific collaborative meta-analysis Berger JS, Bhatt DL, Cannon CP, Chen Z, Jiang L, Jones JB, Mehta SR, Sabatine MS, Steinhubl SR, Topol EJ, Berger PB CRD summary The authors concluded that clopidogrel (...) was effective in reducing the risk of cardiovascular events for both women and men. The authors’ conclusions appear to be reliable, but a risk of error and bias in the review methods should be considered. Authors' objectives To determine the efficacy and safety of clopidogrel for the prevention of cardiovascular events in women and men. Searching MEDLINE and The Cochrane Central Register of Controlled Trials (CENTRAL) were searched for studies published between 1999 and May 2007. The search terms were

DARE.2009

149. Clopidogrel for the treatment of adult patients following acute coronary syndrome

Clopidogrel for the treatment of adult patients following acute coronary syndrome The Therapeutics Initiative | Evidence-Based, Practical Prescription Drug Therapy Information Independent Healthcare Evidence What’s New March 15, 2017 A recent Alberta modeling study suggests that lifetime risk of diabetes is now 50% for non-indigenous Canadians and 80% for First Nations Canadians.1 If true, type 2 diabetes (DM2) will become the most common primary care diagnosis. Costs including … February 3

Therapeutics Letter2009

150. Concomitant use of proton pump inhibitors with clopidogrel may increase risk of readmission after discharge for acute MI

Concomitant use of proton pump inhibitors with clopidogrel may increase risk of readmission after discharge for acute MI Concomitant use of proton pump inhibitors with clopidogrel may increase risk of readmission after discharge for acute MI | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user (...) name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Concomitant use of proton pump inhibitors with clopidogrel may increase risk of readmission after discharge for acute MI Article Text Aetiology Concomitant use of proton pump inhibitors with clopidogrel may increase risk of readmission after discharge for acute MI

Evidence-Based Medicine (Requires free registration)2009

151. The effect of different treatment durations of clopidogrel in patients with non-ST-segment elevation acute coronary syndromes: a systematic review and value of information analysis

The effect of different treatment durations of clopidogrel in patients with non-ST-segment elevation acute coronary syndromes: a systematic review and value of information analysis The effect of different treatment durations of clopidogrel in patients with non-ST-segment elevation acute coronary syndromes: a systematic review and value of information analysis The effect of different treatment durations of clopidogrel in patients with non-ST-segment elevation acute coronary syndromes (...) : a systematic review and value of information analysis Rogowski W, Burch J, Palmer S, Craigs C, Golder S, Woolacott N CRD summary This update review suggested that clopidogrel was effective for reducing adverse cardiovascular events in patients with non-ST-elevation-acute coronary syndrome. There was insufficient evidence to enable conclusions to be drawn on treatment duration and a rebound effect on withdrawal of treatment. This was a generally well-conducted review and the authors' conclusions appear

DARE.2009

152. Impact of duration of clopidogrel prescription on outcome of DES as compared to BMS in primary angioplasty: a meta-regression analysis of randomized trials

Impact of duration of clopidogrel prescription on outcome of DES as compared to BMS in primary angioplasty: a meta-regression analysis of randomized trials Impact of duration of clopidogrel prescription on outcome of DES as compared to BMS in primary angioplasty: a meta-regression analysis of randomized trials Impact of duration of clopidogrel prescription on outcome of DES as compared to BMS in primary angioplasty: a meta-regression analysis of randomized trials De Luca G, Cassetti E, Marino P (...) CRD summary This review concluded that in selected patients who underwent primary angioplasty for ST-segment elevation myocardial infarction, drug-eluting stents (sirolimus and paclitaxel) were effective and safe compared with bare-metal stents and unaffected by duration of clopidogrel prescription. Concerns regarding the interpretation of data and absence of any assessment of study quality suggest that the authors' conclusions should be interpreted cautiously. Authors' objectives To assess

DARE.2009

153. The effect of different treatment durations of clopidogrel in patients with non-ST-segment elevation acute coronary syndromes: a systematic review and value of information analysis

The effect of different treatment durations of clopidogrel in patients with non-ST-segment elevation acute coronary syndromes: a systematic review and value of information analysis The effect of different treatment durations of clopidogrel in patients with non-ST-segment elevation acute coronary syndromes: a systematic review and value of information analysis The effect of different treatment durations of clopidogrel in patients with non-ST-segment elevation acute coronary syndromes (...) : a systematic review and value of information analysis Rogowski W, Burch J, Palmer S, Craigs C, Golder S, Woolacott N Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Rogowski W, Burch J, Palmer S, Craigs C, Golder S, Woolacott N. The effect of different treatment durations of clopidogrel in patients with non-ST-segment elevation acute coronary

Health Technology Assessment (HTA) Database.2009

154. Clopidogrel versus other antiplatelet agents in the secondary prevention of vascular events in adults with cerebrovascular disease: clinical and cost-effectiveness analyses

Clopidogrel versus other antiplatelet agents in the secondary prevention of vascular events in adults with cerebrovascular disease: clinical and cost-effectiveness analyses Clopidogrel versus other antiplatelet agents in the secondary prevention of vascular events in adults with cerebrovascular disease: clinical and cost-effectiveness analyses Clopidogrel versus other antiplatelet agents in the secondary prevention of vascular events in adults with cerebrovascular disease: clinical and cost (...) -effectiveness analyses Banerjee S, Brown A, Hutton B, McGahan L, Asakawa K, Clark M, Severn M, Cox JL, Sharma M Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Banerjee S, Brown A, Hutton B, McGahan L, Asakawa K, Clark M, Severn M, Cox JL, Sharma M. Clopidogrel versus other antiplatelet agents in the secondary prevention of vascular events in adults

Health Technology Assessment (HTA) Database.2009

155. CYP2C19 Genotyping to determine response to clopidogrel

CYP2C19 Genotyping to determine response to clopidogrel CYP2C19 Genotyping to determine response to clopidogrel CYP2C19 Genotyping to determine response to clopidogrel Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Report may be purchased from . Citation CYP2C19 Genotyping to determine response to clopidogrel . Lansdale: HAYES, Inc.. 2009 Authors' objectives Dual (...) antiplatelet therapy with aspirin and clopidogrel (Plavix®; Sanofi-Aventis U.S. LLC) is recommended both in patients after acute myocardial infarction (MI) and in patients undergoing percutaneous coronary intervention (PCI) with stenting. Clopidogrel is a prodrug that requires transformation to an active metabolite in the liver by the cytochrome P450 (CYP) enzymes. The CYP genes are highly polymorphic and recent data suggest that certain alleles, particularly of the CYP2C19 gene located on chromosome 10

Health Technology Assessment (HTA) Database.2009

156. Aspirin plus extended-release dipyridamole and clopidogrel were similarly effective for preventing recurrent stroke

Aspirin plus extended-release dipyridamole and clopidogrel were similarly effective for preventing recurrent stroke Aspirin plus extended-release dipyridamole and clopidogrel were similarly effective for preventing recurrent stroke | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name (...) or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Aspirin plus extended-release dipyridamole and clopidogrel were similarly effective for preventing recurrent stroke Article Text Therapeutics Aspirin plus extended-release dipyridamole and clopidogrel were similarly effective for preventing recurrent stroke Statistics from

Evidence-Based Medicine (Requires free registration)2009

157. Effect of clopidogrel added to aspirin in patients with atrial fibrillation.

Effect of clopidogrel added to aspirin in patients with atrial fibrillation. 19336502 2009 05 14 2009 05 19 2013 11 21 1533-4406 360 20 2009 May 14 The New England journal of medicine N. Engl. J. Med. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. 2066-78 10.1056/NEJMoa0901301 Vitamin K antagonists reduce the risk of stroke in patients with atrial fibrillation but are considered unsuitable in many patients, who usually receive aspirin instead. We investigated (...) the hypothesis that the addition of clopidogrel to aspirin would reduce the risk of vascular events in patients with atrial fibrillation. A total of 7554 patients with atrial fibrillation who had an increased risk of stroke and for whom vitamin K-antagonist therapy was unsuitable were randomly assigned to receive clopidogrel (75 mg) or placebo, once daily, in addition to aspirin. The primary outcome was the composite of stroke, myocardial infarction, non-central nervous system systemic embolism, or death

NEJM2009

158. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials.

Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. 19726078 2009 09 21 2009 10 02 2015 11 19 1474-547X 374 9694 2009 Sep 19 Lancet (London, England) Lancet Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. 989-97 10.1016/S0140-6736(09)61525-7 Proton-pump inhibitors (PPIs) are often prescribed (...) in combination with thienopyridines. Conflicting data exist as to whether PPIs diminish the efficacy of clopidogrel. We assessed the association between PPI use, measures of platelet function, and clinical outcomes for patients treated with clopidogrel or prasugrel. In the PRINCIPLE-TIMI 44 trial, the primary outcome was inhibition of platelet aggregation at 6 h assessed by light-transmission aggregometry. In the TRITON-TIMI 38 trial, the primary endpoint was the composite of cardiovascular death

Lancet2009

159. Ticagrelor versus clopidogrel in patients with acute coronary syndromes.

Ticagrelor versus clopidogrel in patients with acute coronary syndromes. 19717846 2009 09 10 2009 09 21 2016 07 02 1533-4406 361 11 2009 Sep 10 The New England journal of medicine N. Engl. J. Med. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. 1045-57 10.1056/NEJMoa0904327 Ticagrelor is an oral, reversible, direct-acting inhibitor of the adenosine diphosphate receptor P2Y12 that has a more rapid onset and more pronounced platelet inhibition than clopidogrel (...) . In this multicenter, double-blind, randomized trial, we compared ticagrelor (180-mg loading dose, 90 mg twice daily thereafter) and clopidogrel (300-to-600-mg loading dose, 75 mg daily thereafter) for the prevention of cardiovascular events in 18,624 patients admitted to the hospital with an acute coronary syndrome, with or without ST-segment elevation. At 12 months, the primary end point--a composite of death from vascular causes, myocardial infarction, or stroke--had occurred in 9.8% of patients receiving

NEJM2009

160. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.

Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. 19249633 2009 03 02 2009 03 12 2015 11 19 1474-547X 373 9665 2009 Feb 28 Lancet (London, England) Lancet Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. 723-31 (...) 10.1016/S0140-6736(09)60441-4 Mechanical reperfusion with stenting for ST-elevation myocardial infarction (STEMI) is supported by dual antiplatelet treatment with aspirin and clopidogrel. Prasugrel, a potent and rapid-acting thienopyridine, is a potential alternative to clopidogrel. We aimed to assess prasugrel versus clopidogrel in patients undergoing percutaneous coronary intervention (PCI) for STEMI. We undertook a double-blind, randomised controlled trial in 707 sites in 30 countries. 3534

Lancet2009